Insulet Co. (NASDAQ:PODD) has received a consensus recommendation of “Buy” from the twenty research firms that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $64.42.
Several brokerages have commented on PODD. BidaskClub raised Insulet from a “sell” rating to a “hold” rating in a research report on Friday, January 26th. Zacks Investment Research raised Insulet from a “sell” rating to a “hold” rating in a research report on Thursday, February 1st. Robert W. Baird lifted their price target on Insulet from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Barclays lifted their price target on Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. Finally, Jefferies Group lifted their price target on Insulet from $58.00 to $67.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd.
Shares of Insulet (NASDAQ PODD) traded down $1.01 during midday trading on Tuesday, reaching $72.46. The company’s stock had a trading volume of 466,611 shares, compared to its average volume of 537,257. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. The company has a market cap of $4,233.16, a P/E ratio of -144.92 and a beta of 1.59. Insulet has a 52 week low of $38.43 and a 52 week high of $78.65.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/insulet-co-podd-receives-consensus-rating-of-buy-from-analysts.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.